NCT07110311 Impact of Pet Cats on Nasal and Gut Microbiota in Patients With Cat Allergen Allergy
| NCT ID | NCT07110311 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Condition | Allergic Rhinitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-11-14 |
| Primary Completion | 2026-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-11-14 with a primary completion date of 2026-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
It has been reported that the incidence of allergic rhinitis (AR) is as high as 24.1% in adults and 16.8% in children in China. A study explored the changes in the incidence of AR in China, and the study showed that the incidence of AR in many cities in China increased significantly from 2005 to 2011. The latest Chinese guidelines for the diagnosis and treatment of allergic rhinitis pointed out that AR is an independent risk factor for asthma, and 40% of AR patients can be complicated with asthma. CARRAD reported that in adult asthma patients who received skin prick test or serum specific IgE (sIgE) for allergens, The positive rates of at least one allergen were 65.4% and 75.4%, respectively. With the acceleration of urbanization and the improvement of people's economic level, more and more families keep pets. Pets can promote people's physical and mental health, but there are also more and more people who are allergic to pets. Some studies have shown that pets are the third major allergen of respiratory allergic diseases, next to dust mites and pollen. Cats are by far one of the most popular pets, but in recent years, the prevalence of cat allergen has gradually increased. Animal allergens are present in saliva, urine, and dander, and they spread into the environment by adhering to the hair and dander of the animals, such that even in homes without pets, the level of allergens in the environment is sufficient to sensitize people. However, at present, the microbial impact of the microorganisms carried by pet cats on their owners and the living environment is unknown.
Eligibility Criteria
Inclusion Criteria: * Adult patients (18-65 years). * Patients with moderate to severe dust mite allergic rhinitis were diagnosed based on clinical history and positive cat allergen sensitization tests (skin prick test and/or specific IgE). * Patients who visited the Department of Otolaryngology of the First Affiliated Hospital of Nanjing Medical University. Exclusion Criteria: * Patients who refused to accept specimen and questionnaire collection. * Patients who had nasal diseases other than allergic rhinitis, such as nasal papilloma and nasal malignant tumor.
Contact & Investigator
Lei Cheng, PhD
STUDY CHAIR
The First Affiliated Hospital, Nanjing Medical University
Frequently Asked Questions
Who can join the NCT07110311 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Allergic Rhinitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07110311 currently recruiting?
Yes, NCT07110311 is actively recruiting participants. Contact the research team at chenglei@jsph.org.cn for enrollment information.
Where is the NCT07110311 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT07110311 clinical trial?
NCT07110311 is sponsored by The First Affiliated Hospital with Nanjing Medical University. The principal investigator is Lei Cheng, PhD at The First Affiliated Hospital, Nanjing Medical University. The trial plans to enroll 100 participants.